![\"\"](\"https:\/\/web.uri.edu\/wp-content\/uploads\/sites\/1497\/MindImmune-logo-300x212-1.jpg\"){kind=logo}
<\/h2>\n<\/h2>\nMindImmune Therapeutics, Inc.<\/strong> a small pharmaceutical company with an impact that is emerging daily, is based in Kingston, at the University of Rhode Island. The company is developing first-in-class therapeutic drugs targeting the immune system to treat diseases of the central nervous system, including Alzheimer\u2019s disease. The company recently announced its closing on a $12.4-million Series A financing. MindImmune<\/strong> is RI-INBRE’s Centralized Research Core Facility’s (CRCF) major industrial user, utilizing a wide range of instrumentation.<\/p>\n The drug discovery company, was founded in 2016 by Stevin Zorn, Ph.D., Frank Menniti, Ph.D., and Robert Nelson, Ph.D., all former colleagues at Pfizer\u2019s Worldwide Research & Development. The current team has nearly one hundred years of combined experience in the pharmaceutical industry and are experts in central nervous system drug discovery. The human immune and central nervous systems are closely connected, and immune system dysfunction is a critical factor in brain impairment. MindImmune<\/strong>\u2019s scientists have been instrumental in recognizing therapeutic opportunities to target the immune system in order to treat neurological disorders and brain diseases.<\/p>\n The public-private collaboration established between MindImmune<\/strong>, and URI\u2019s George and Anne Ryan Institute for Neuroscience created a nucleus for biology, pharmacology, and neuroscience collaboration in Rhode Island.<\/p>\n Menniti, Chief Science Officer, said each principal \u201cwas appointed a faculty position as Ryan Research Professors of Neuroscience\u201d in August 2016, and the MindImmune<\/strong> team teaches graduate-level Neuroscience courses within the Interdisciplinary Neuroscience Program at the university.\u201d He expressed his thanks to past President David Dooley and everyone at URI that welcomed them with open arms.<\/p>\n Zorn, President and Chief Executive Officer, stated they \u201clooked at a lot of lab space and landed at URI, and still feel it is the place to be, in a vibrant community where MindImmune<\/strong> can thrive.\u201d Everyone expressed their enthusiasm about being here and their partnership with URI and the Ryan Institute.<\/p>\n RI-INBRE\u2019s Centralized Research Core Facility (CRCF)<\/strong> is a one-of-a-kind facility in the state of Rhode Island containing over $3.5 million of state-of-the-art scientific instrumentation and is across the hall from MindImmune<\/strong>\u2019s lab. Menniti shared that they \u201cneed a lot of resources and use of RI-INBRE\u2019s lab allows them to cost-effectively sustain their program.\u201d<\/p>\n \u201cThere are millions of dollars of instrumentation that MindImmune<\/strong> has access to at RI-INBRE\u2019s CRCF<\/strong> that we do not have to purchase, it\u2019s not just dollars and cents, it makes sense,\u201d said Zorn. \u201cThe equipment is running constantly and avoids the issue of consistently recalibrating it due to repeated startups and shutdowns.\u201d He also revealed that \u201cBob is living his dream advancing the science that he built on during his career. Such is enabled by our collaboration with and his usage of the RI-INBRE<\/strong> center to advance our company goals of delivering a much-needed Alzheimer\u2019s disease therapeutic.\u201d<\/p>\n Nelson, Vice President of Exploratory Biology disclosed \u201cWe had two \u2018Eureka!\u2019 moments happen as we watched data read out from RI-INBRE center instruments. The first revealed a new way to track pathological immune cell recruitment into the brains of \u2018Alzheimer mice,\u2019 and the second revealed a therapeutic target for blocking that recruitment. Together these findings have helped chart the course for our path forward as a company.\u201d<\/p>\n Visit MindImmune Therapeutics<\/a> Explore the CRCF<\/a><\/p>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Industry User: MindImmune Therapeutics, Inc. MindImmune Therapeutics, Inc. a small pharmaceutical company with an impact that is emerging daily, is based in Kingston, at the University of Rhode Island. The company is developing first-in-class therapeutic drugs targeting the immune system to treat diseases of the central nervous system, including Alzheimer\u2019s disease. The company recently announced […]<\/p>\n","protected":false},"author":1036,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[78,637],"tags":[738,611,712,713,253,739],"class_list":["post-32376","post","type-post","status-publish","format-standard","hentry","category-core","category-enews","tag-alzheimers","tag-crcf","tag-enews-2022-summer","tag-mindimmune","tag-neuroscience","tag-ryan-institute"],"acf":[],"_links":{"self":[{"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/posts\/32376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/users\/1036"}],"replies":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/comments?post=32376"}],"version-history":[{"count":5,"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/posts\/32376\/revisions"}],"predecessor-version":[{"id":32865,"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/posts\/32376\/revisions\/32865"}],"wp:attachment":[{"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/media?parent=32376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/categories?post=32376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/web.uri.edu\/riinbre\/wp-json\/wp\/v2\/tags?post=32376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Charles Nolan and Joseph Hedde, both Associate Research Fellows, shared that they currently use specific instrumentation, but are delighted to know that as their needs change as the research evolves, that RI-INBRE is there to help.<\/blockquote><\/div><\/section>CRCF instrumentation<\/strong> currently used by MindImmune<\/strong> includes Cell Culture Hood, and Xcelligence, a Tabletop Centrifuge, an Azure Sapphire Imager, two LI-COR Imaging: C-Digit Blot Scanner and Odyssey IR Imager Scanner, a Microcentrifuge, the EVOS M7000 Microscope, and four Spectrometers: Genesys 50, iD3 and M2 Plate Readers, and NanoDrop.<\/p>\n